all news now is GILD's drug. doesn't matter that it has issues and side effects per the article. analysts are jumping all in GILD and dumping VRTX. we'll see the low 30's soon. CF better work or that's it for this company. They need trial results from some other drug like really fast. we won't see 50 this year. might not see it till 2014. pretty damn sad if you ask me.